Found: 11
Select item for more details and to access through your institution.
An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data.
- Published in:
- Pharmacology Research & Perspectives, 2020, v. 8, n. 3, p. 1, doi. 10.1002/prp2.599
- By:
- Publication type:
- Article
The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease.
- Published in:
- EMBO Molecular Medicine, 2018, v. 10, n. 11, p. N.PAG, doi. 10.15252/emmm.201809316
- By:
- Publication type:
- Article
Industry Perspective on Therapeutic Peptide Drug–Drug Interaction Assessments During Drug Development: A European Federation of Pharmaceutical Industries and Associations White Paper.
- Published in:
- Clinical Pharmacology & Therapeutics, 2023, v. 113, n. 6, p. 1199, doi. 10.1002/cpt.2847
- By:
- Publication type:
- Article
Therapeutic Protein Drug Interactions: A White Paper From the International Consortium for Innovation and Quality in Pharmaceutical Development.
- Published in:
- Clinical Pharmacology & Therapeutics, 2023, v. 113, n. 6, p. 1185, doi. 10.1002/cpt.2814
- By:
- Publication type:
- Article
Ribociclib Drug‐Drug Interactions: Clinical Evaluations and Physiologically‐Based Pharmacokinetic Modeling to Guide Drug Labeling.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 3, p. 575, doi. 10.1002/cpt.1950
- By:
- Publication type:
- Article
Estimation of fractions metabolized by hepatic CYP enzymes using a concept of inter-system extrapolation factors (ISEFs) - a comparison with the chemical inhibition method.
- Published in:
- Drug Metabolism & Personalized Therapy, 2017, v. 32, n. 4, p. 191, doi. 10.1515/dmpt-2017-0024
- By:
- Publication type:
- Article
Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
- Published in:
- Drug Metabolism & Personalized Therapy, 2019, v. 34, n. 2, p. N.PAG, doi. 10.1515/dmpt-2018-0042
- By:
- Publication type:
- Article
Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction.
- Published in:
- Drug Metabolism & Personalized Therapy, 2016, v. 31, n. 4, p. 221, doi. 10.1515/dmpt-2016-0028
- By:
- Publication type:
- Article
Solubilization and hydrophobicity test by Triton X-114-partitioning of NADPH-protochlorophyllide oxidoreductase from the unicellular alga Scenedesmus obliquus, mutant C-2A″.
- Published in:
- Physiologia Plantarum, 1995, v. 95, n. 1, p. 141, doi. 10.1111/j.1399-3054.1995.tb00820.x
- By:
- Publication type:
- Article
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 2, p. 155, doi. 10.1007/s40262-023-01338-z
- By:
- Publication type:
- Article
Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling.
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 1, p. 118, doi. 10.1111/cts.13126
- By:
- Publication type:
- Article